BioVie (BIVI) to Announce Earnings on Monday

BioVie (NASDAQ:BIVI) is projected to issue its Q4 2026 results before the market opens on Monday, August 24th. Analysts expect BioVie to announce earnings of ($0.52) per share for the quarter. Investors may visit the the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 7:00 AM ET.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.18).

BioVie Stock Up 4.8%

BIVI opened at $1.95 on Friday. BioVie has a twelve month low of $0.82 and a twelve month high of $3.79. The company has a fifty day moving average of $1.67 and a 200-day moving average of $1.50. The stock has a market cap of $16.48 million, a PE ratio of -0.62 and a beta of 0.60.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioVie in a research report on Friday, July 17th. Wall Street Zen raised BioVie to a “sell” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioVie presently has an average rating of “Sell”.

Institutional Investors Weigh In On BioVie

Hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC boosted its position in shares of BioVie by 283.7% during the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after purchasing an additional 40,000 shares in the last quarter. XTX Topco Ltd acquired a new position in BioVie during the 2nd quarter worth approximately $40,000. Jane Street Group LLC bought a new position in BioVie in the second quarter worth approximately $57,000. Squarepoint Ops LLC bought a new position in BioVie in the third quarter worth approximately $63,000. Finally, Two Sigma Investments LP acquired a new stake in BioVie in the third quarter valued at approximately $62,000. 4.59% of the stock is owned by institutional investors.

About BioVie

BioVie Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver?related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life?threatening condition marked by elevated neurotoxins in patients with advanced liver disease.